Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Continues Divestitures To Close Allergan Deal With Sale To Impax

Executive Summary

Impax will gain 15 approved generics and three pipeline assets, which will help address offset lower revenues of two of its existing top-sellers.

Advertisement

Related Content

Consolidation in Generics Sector As Impax Merges With Amneal
Consolidation in Generics Sector As Impax Merges With Amneal
Teva Embarks On New Phase With FTC Clearance Of Allergan Generics
Teva, Allergan Probably Won't Need More Divestments To Get FTC Approval
Teva’s Rosy View For A Happy Union With Allergan Generics
Nichi-Iko Buys Sagent To Strengthen US Biosimilars Presence
Nichi-Iko Buys Sagent To Strengthen US Biosimilars Presence
Stockwatch: Don't Fear The Pricing Reaper
Teva to buy Allergan Generics; Mylan off the hook but Perrigo still wriggling
More FDA inspection problems plague Impax

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC065478

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel